Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 3 (2006), Issue 6 (June)

1. Adverse impact of a history of violence for women with breast, cervical, endometrial, or ovarian cancer.
   Obstet Gynecol, 107(6): 1330-6. [Abstract] [Full-text]
2. Detection of mRNA levels for the estrogen alpha, estrogen beta and androgen nuclear receptor genes in archival breast cancer tissue.
   Cancer Lett, 237(2): 248-55. [Abstract] [Full-text]
3. DNA hypermethylation in breast cancer and its association with clinicopathological features.
   Cancer Lett, 237(2): 272-80. [Abstract] [Full-text]
4. Cancer and leukemia group B breast committee: decades of progress and plans for the future.
   Clin Cancer Res, 12(11): 3576s-80s. [Abstract] [Full-text]
5. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.
   Lancet Oncol, 7(6): 467-71. [Abstract] [Full-text]
6. ErbB receptor tyrosine kinase network inhibition radiosensitizes carcinoma cells.
   Int J Radiat Oncol Biol Phys, 65(3): 851-8. [Abstract] [Full-text]
7. Impact of radiotherapy in the risk of esophageal cancer as subsequent primary cancer after breast cancer.
   Int J Radiat Oncol Biol Phys, 65(3): 699-704. [Abstract] [Full-text]
8. Biology of ductal carcinoma in situ classification based on biologic potential.
   Am J Clin Oncol, 29(3): 305-10. [Abstract] [Full-text]
9. Lymph node-based prognostics: limitations with individualized cancer treatment.
   Am J Clin Oncol, 29(3): 298-304. [Abstract] [Full-text]
10. Treatment of metastatic breast cancer with vinorelbine and docetaxel.
    Am J Clin Oncol, 29(3): 276-80. [Abstract] [Full-text]
11. Phase I-II study of pegylated liposomal doxorubicin combined with weekly paclitaxel as first-line treatment in patients with metastatic breast cancer.
    Am J Clin Oncol, 29(3): 267-75. [Abstract] [Full-text]
12. Breast cancer screening in women surviving Hodgkin disease.
    Am J Clin Oncol, 29(3): 258-66. [Abstract] [Full-text]
13. HER-2 amplification in tubular carcinoma of the breast.
    Am J Clin Pathol, 126(1): 55-8. [Abstract] [Full-text]
14. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
    JAMA, 295(21): 2492-502. [Abstract] [Full-text]
15. Retrospective cost-effectiveness analysis of screening mammography.
    J Natl Cancer Inst, 98(11): 774-82. [Abstract] [Full-text]
16. Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with MCF-7 human breast cancer xenografts.
    Int J Cancer, 119(4): 925-31. [Abstract] [Full-text]
17. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.
    Int J Cancer, 119(4): 944-54. [Abstract] [Full-text]
18. Effects of different phases of an invitational screening program on breast cancer incidence.
    Int J Cancer, 119(4): 920-4. [Abstract] [Full-text]
19. Treatment options for older woman with early breast cancer.
    Expert Rev Anticancer Ther, 6(6): 941-50. [Abstract] [Full-text]
20. Extended adjuvant therapy with letrozole: reducing the risk of recurrence.
    Expert Rev Anticancer Ther, 6(6): 849-59. [Abstract] [Full-text]
21. Anastrozole for breast cancer: recent advances and ongoing challenges.
    Expert Rev Anticancer Ther, 6(6): 839-48. [Abstract] [Full-text]
22. Chromosome 5 imbalance mapping in breast tumors from BRCA1 and BRCA2 mutation carriers and sporadic breast tumors.
    Int J Cancer, 119(5): 1052-60. [Abstract] [Full-text]
23. Methodological issues in international comparison of interval breast cancers.
    Int J Cancer, 119(5): 1158-63. [Abstract] [Full-text]
24. KIF14 mRNA expression is a predictor of grade and outcome in breast cancer.
    Int J Cancer, 119(5): 1088-94. [Abstract] [Full-text]
25. Social class is an important and independent prognostic factor of breast cancer mortality.
    Int J Cancer, 119(5): 1145-51. [Abstract] [Full-text]
26. Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: relationship with cell cycle changes and apoptosis, and identification of novel targets of p53.
    Int J Cancer, 119(5): 1164-75. [Abstract] [Full-text]
27. Germline mutations 657del5 of the NBS1 gene contribute significantly to the incidence of breast cancer in Central Poland.
    Int J Cancer, 119(2): 472-5. [Abstract] [Full-text]
28. Biomarker analysis on breast ductal lavage cells in women with and without breast cancer.
    Int J Cancer, 119(2): 359-64. [Abstract] [Full-text]
29. Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study.
    Int J Cancer, 119(2): 467-71. [Abstract] [Full-text]
30. The receptor expression pattern in ductal carcinoma in situ predicts recurrence.
    Am J Surg, 192(1): 68-71. [Abstract] [Full-text]
31. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
    Am J Surg, 192(1): 58-62. [Abstract] [Full-text]
32. Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.
    Am J Physiol Cell Physiol, 291(1): C40-9. [Abstract] [Full-text]
33. Comparisons of resource costs and success rates between immediate and delayed breast reconstruction using DIEP or SIEA flaps under a well-controlled clinical trial.
    Plast Reconstr Surg, 117(7): 2139-42; discussion 2143-4. [Abstract] [Full-text]
34. A two-year prospective analysis of trunk function in TRAM breast reconstructions.
    Plast Reconstr Surg, 117(7): 2131-8. [Abstract] [Full-text]
35. Real-time intraoperative detection of breast cancer axillary lymph node metastases using a green fluorescent protein-expressing herpes virus.
    Ann Surg, 243(6): 824-30; discussion 830-2. [Abstract] [Full-text]
36. Balanced t(11;15)(q23;q15) in a TP53+/+ breast cancer patient from a Li-Fraumeni syndrome family.
    Cancer Genet Cytogenet, 168(1): 50-8. [Abstract] [Full-text]
37. Gross rearrangements in BRCA1 but not BRCA2 play a notable role in predisposition to breast and ovarian cancer in high-risk families of German origin.
    Cancer Genet Cytogenet, 168(1): 44-9. [Abstract] [Full-text]
38. Label-free semiquantitative peptide feature profiling of human breast cancer and breast disease sera via two-dimensional liquid chromatography-mass spectrometry.
    Mol Cell Proteomics, 5(6): 1095-104. [Abstract] [Full-text]
39. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes.
    Endocrinology, 147(7): 3484-500. [Abstract] [Full-text]
40. Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins.
    Endocrinology, 147(7): 3285-95. [Abstract] [Full-text]
41. Prognostic value of nodal ratios in node-positive breast cancer.
    J Clin Oncol, 24(18): 2910-6. [Abstract] [Full-text]
42. Prospective changes in quality of life after ductal carcinoma-in-situ: results from the Nurses' Health Study.
    J Clin Oncol, 24(18): 2822-7. [Abstract] [Full-text]
43. Sexual problems in younger women after breast cancer surgery.
    J Clin Oncol, 24(18): 2815-21. [Abstract] [Full-text]
44. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
    J Clin Oncol, 24(18): 2786-92. [Abstract] [Full-text]
45. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort.
    J Clin Oncol, 24(18): 2757-64. [Abstract] [Full-text]
46. Use and outcomes of adjuvant chemotherapy in older women with breast cancer.
    J Clin Oncol, 24(18): 2750-6. [Abstract] [Full-text]
47. Randomized controlled trial of weight training and lymphedema in breast cancer survivors.
    J Clin Oncol, 24(18): 2765-72. [Abstract] [Full-text]
48. Stroke rates and risk factors in patients treated with radiation therapy for early-stage breast cancer.
    J Clin Oncol, 24(18): 2779-85. [Abstract] [Full-text]
49. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis.
    J Clin Oncol, 24(18): 2743-9. [Abstract] [Full-text]
50. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
    J Clin Oncol, 24(18): 2773-8. [Abstract] [Full-text]
51. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
    J Clin Oncol, 24(18): 2793-9. [Abstract] [Full-text]
52. Clinical and histopathologic observations of the action of imiquimod in an epithelioid hemangioendothelioma and Paget's mammary disease.
    J Am Acad Dermatol, 55(1): 75-9. [Abstract] [Full-text]
53. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
    J Surg Res, 134(1): 44-51. [Abstract] [Full-text]
54. Patient outcomes after axillary lymph node dissection for breast cancer: use of postoperative continuous local anesthesia infusion.
    J Surg Res, 134(1): 124-32. [Abstract] [Full-text]
55. Retinoic acid and ascorbic acid act synergistically in inhibiting human breast cancer cell proliferation.
    J Nutr Biochem, 17(7): 454-62. [Abstract] [Full-text]
56. Cytotoxic response of breast cancer cell lines, MCF 7 and T 47 D to triphala and its modification by antioxidants.
    Cancer Lett, 238(2): 304-13. [Abstract] [Full-text]
57. Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha.
    Biochem Biophys Res Commun, 346(1): 252-8. [Abstract] [Full-text]
58. Cadmium exposure and breast cancer risk.
    J Natl Cancer Inst, 98(12): 869-73. [Abstract] [Full-text]
59. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    JAMA, 295(23): 2742-51. [Abstract] [Full-text]
60. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    JAMA, 295(23): 2727-41. [Abstract] [Full-text]
61. Randomized clinical trial of the effect of quilting latissimus dorsi flap donor site on seroma formation.
    Br J Surg, 93(7): 825-30. [Abstract] [Full-text]
62. Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer.
    Br J Surg, 93(7): 820-4. [Abstract] [Full-text]
63. Systematic review and meta-analysis of the use of fibrin sealant to prevent seroma formation after breast cancer surgery.
    Br J Surg, 93(7): 810-9. [Abstract] [Full-text]
64. Differentiating benign from malignant solid breast masses: comparison of two-dimensional and three-dimensional US.
    Radiology, 240(1): 26-32. [Abstract] [Full-text]
65. Symmetrization reduction mammaplasty combined with sentinel node biopsy in patients operated for contralateral breast cancer.
    J Surg Oncol, 94(1): 9-15. [Abstract] [Full-text]
66. A prospective study of conservative surgery without radiation therapy in select patients with Stage I breast cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1149-54. [Abstract] [Full-text]
67. Fifteen-year results of a randomized prospective trial of hyperfractionated chest wall irradiation versus once-daily chest wall irradiation after chemotherapy and mastectomy for patients with locally advanced noninflammatory breast cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1155-60. [Abstract] [Full-text]
68. Change in volume of lumpectomy cavity during external-beam irradiation of the intact breast.
    Int J Radiat Oncol Biol Phys, 65(4): 1161-4. [Abstract] [Full-text]
69. Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
    Int J Radiat Oncol Biol Phys, 65(4): 1165-9. [Abstract] [Full-text]
70. Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo.
    Biochem Biophys Res Commun, 346(3): 778-85. [Abstract] [Full-text]
71. Of humans and canines: Immunohistochemical analysis of PCNA, Bcl-2, p53, cytokeratin and ER in mammary tumours.
    Res Vet Sci, 81(2): 218-24. [Abstract] [Full-text]
72. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer.
    J Clin Oncol, 24(19): 3039-47. [Abstract] [Full-text]
73. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
    J Clin Oncol, 24(19): 3032-8. [Abstract] [Full-text]
74. Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide?
    J Clin Oncol, 24(19): 3048-55. [Abstract] [Full-text]
75. Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
    J Clin Oncol, 24(19): 3013-8. [Abstract] [Full-text]
76. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole.
    J Clin Oncol, 24(19): 3019-25. [Abstract] [Full-text]
77. Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.
    J Clin Oncol, 24(19): 3026-31. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.